Valeur20202021202220232024TTMFrais de vente, généraux et administratifs747 M818 M828 M926 M1.1 B—Recherche et développement226 M230 M236 M274 M320 M—Résultat d'exploitation332 M389 M695 M813 M842 M—Total des produits hors exploitation——————Charges d'intérêts, nettes des intérêts capitalisés——————Résultat hors exploitation, hors charges d'intérêts——————Revenus/dépenses exceptionnels——————Résultat avant impôts361 M426 M734 M862 M900 M—Part des actionnaires dans le résultat——————Impôts125 M115 M186 M194 M229 M—Intérêts ne donnant pas le contrôle / intérêts minoritaires————8 M—Autres produits/charges après impôts——————Résultat net avant activités abandonnées236 M311 M548 M668 M671 M—Activités abandonnées——————Résultat net236 M311 M548 M668 M671 M—Ajustement de dilution——————Dividendes privilégiés——————Résultat net dilué revenant aux actionnaires ordinaires——————Bénéfice par action de base (BPA de base)——————Bénéfice par action dilué (BPA dilué)——————Nombre moyen d'actions de base en circulation——————Nombre d'actions en circulation après dilution——————EBITDA——————EBIT1.52 B1.71 B1.99 B2.2 B2.42 B—Coût des ventes1.19 B1.32 B1.3 B1.39 B1.58 B—Autres coûts des ventes——————Amortissements (flux de trésorerie)——————
Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr.